A phase Ib/II trial of INO-5401 in combination with atezolizumab and INO-9012 in patients with advanced bladder cancer

Trial Profile

A phase Ib/II trial of INO-5401 in combination with atezolizumab and INO-9012 in patients with advanced bladder cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Status changed from planning to recruiting, according to an Inovio Pharmaceuticals media release.
    • 08 Aug 2017 According to an Inovio Pharmaceuticals media release, the company anticipates to initiate this trial in the second half of 2017.
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top